APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents and Insulin Analogues

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Hypoglycemic Agents and Insulin Analogues Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025184 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents and Insulin Analogues Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents and Insulin Analogues Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents and Insulin Analogues Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents and Insulin Analogues Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents and Insulin Analogues Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents and Insulin Analogues market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Hypoglycemic Agents and Insulin Analogues is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Hypoglycemic Agents and Insulin Analogues is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents and Insulin Analogues is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Hypoglycemic Agents and Insulin Analogues is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Hypoglycemic Agents and Insulin Analogues include Tonghua Dongbao, Novo Nordisk, Eli Lilly, Jiangsu Wanbang, United Laboratory, Sanofi-Aventis, Ganlee and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Hypoglycemic Agents and Insulin Analogues market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Hypoglycemic Agents and Insulin Analogues and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Hypoglycemic Agents and Insulin Analogues sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Hypoglycemic Agents and Insulin Analogues market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Hypoglycemic Agents and Insulin Analogues Segment by Company

Tonghua Dongbao

Novo Nordisk

Eli Lilly

Jiangsu Wanbang

United Laboratory

Sanofi-Aventis

Ganlee

Biocon

Oral Hypoglycemic Agents and Insulin Analogues Segment by Type

Alpha-glucosidase Inhibitors

Insulin Secretagogues

Insulin Sensitizers

Oral Hypoglycemic Agents and Insulin Analogues Segment by Application

Hospitals

Drug Store

Others

Oral Hypoglycemic Agents and Insulin Analogues Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents and Insulin Analogues market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and Insulin Analogues and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents and Insulin Analogues.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Hypoglycemic Agents and Insulin Analogues market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents and Insulin Analogues manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Hypoglycemic Agents and Insulin Analogues in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Hypoglycemic Agents and Insulin Analogues in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Hypoglycemic Agents and Insulin Analogues Industry Trends Table 2. Oral Hypoglycemic Agents and Insulin Analogues Industry Drivers Table 3. Oral Hypoglycemic Agents and Insulin Analogues Industry Opportunities and Challenges Table 4. Oral Hypoglycemic Agents and Insulin Analogues Industry Restraints Table 5. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturers Table 9. Global Oral Hypoglycemic Agents and Insulin Analogues Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Oral Hypoglycemic Agents and Insulin Analogues Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Hypoglycemic Agents and Insulin Analogues Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers, Product Type & Application Table 13. Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Hypoglycemic Agents and Insulin Analogues by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alpha-glucosidase Inhibitors Table 17. Major Manufacturers of Insulin Secretagogues Table 18. Major Manufacturers of Insulin Sensitizers Table 19. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (k units) Table 21. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2027-2032) & (k units) Table 22. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2026) Table 23. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2027-2032) Table 24. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021-2026) & (k units) Table 26. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2027-2032) & (k units) Table 27. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2026) Table 28. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Drug Store Table 31. Major Manufacturers of Others Table 32. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (k units) Table 34. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2027-2032) & (k units) Table 35. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2026) Table 36. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2027-2032) Table 37. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021-2026) & (k units) Table 39. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2027-2032) & (k units) Table 40. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2026) Table 41. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2027-2032) Table 42. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2026) & (k units) Table 44. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2021-2026) Table 45. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 49. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 50. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 52. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 59. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2021-2026) Table 63. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2027-2032) Table 64. Tonghua Dongbao Company Information Table 65. Tonghua Dongbao Business Overview Table 66. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 68. Tonghua Dongbao Recent Development Table 69. Novo Nordisk Company Information Table 70. Novo Nordisk Business Overview Table 71. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 73. Novo Nordisk Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Jiangsu Wanbang Company Information Table 80. Jiangsu Wanbang Business Overview Table 81. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 83. Jiangsu Wanbang Recent Development Table 84. United Laboratory Company Information Table 85. United Laboratory Business Overview Table 86. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 88. United Laboratory Recent Development Table 89. Sanofi-Aventis Company Information Table 90. Sanofi-Aventis Business Overview Table 91. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 93. Sanofi-Aventis Recent Development Table 94. Ganlee Company Information Table 95. Ganlee Business Overview Table 96. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 98. Ganlee Recent Development Table 99. Biocon Company Information Table 100. Biocon Business Overview Table 101. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 103. Biocon Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Oral Hypoglycemic Agents and Insulin Analogues Distributors List Table 107. Oral Hypoglycemic Agents and Insulin Analogues Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Product Image Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (2021-2032) & (k units) Figure 5. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Analogues Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alpha-glucosidase Inhibitors Image Figure 9. Insulin Secretagogues Image Figure 10. Insulin Sensitizers Image Figure 11. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2032) Figure 14. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Drug Store Image Figure 19. Others Image Figure 20. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2032) Figure 23. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2032) Figure 26. North America Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 28. U.S. Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 33. Germany Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 40. China Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 48. Brazil Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Oral Hypoglycemic Agents and Insulin Analogues Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032) & (US$ Million) Figure 59. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032) & (US$ Million) Figure 61. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Oral Hypoglycemic Agents and Insulin Analogues Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Oral Hypoglycemic Agents and Insulin Analogues Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-glucosidase Inhibitors
  • Insulin Secretagogues
  • Insulin Sensitizers
Applications
  • Hospitals
  • Drug Store
  • Others
Companies covered
  • Tonghua Dongbao
  • Novo Nordisk
  • Eli Lilly
  • Jiangsu Wanbang
  • United Laboratory
  • Sanofi-Aventis
  • Ganlee
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Hypoglycemic Agents and Insulin Analogues Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Hypoglycemic Agents and Insulin Analogues Market Dynamics
  1. 2.1 Oral Hypoglycemic Agents and Insulin Analogues Industry Trends
  2. 2.2 Oral Hypoglycemic Agents and Insulin Analogues Industry Drivers
  3. 2.3 Oral Hypoglycemic Agents and Insulin Analogues Industry Opportunities and Challenges
  4. 2.4 Oral Hypoglycemic Agents and Insulin Analogues Industry Restraints
3 Oral Hypoglycemic Agents and Insulin Analogues Market by Manufacturers
  1. 3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Hypoglycemic Agents and Insulin Analogues Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Hypoglycemic Agents and Insulin Analogues Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers, Product Type & Application
  7. 3.7 Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Analogues Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Hypoglycemic Agents and Insulin Analogues Tier 1, Tier 2, and Tier 3
4 Oral Hypoglycemic Agents and Insulin Analogues Market by Type
  1. 4.1 Oral Hypoglycemic Agents and Insulin Analogues Type Introduction
  2. 4.1.1 Alpha-glucosidase Inhibitors
  3. 4.1.2 Insulin Secretagogues
  4. 4.1.3 Insulin Sensitizers
  5. 4.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type
  6. 4.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2032)
  8. 4.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2032)
  9. 4.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type
  10. 4.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021-2032)
  12. 4.3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2032)
5 Oral Hypoglycemic Agents and Insulin Analogues Market by Application
  1. 5.1 Oral Hypoglycemic Agents and Insulin Analogues Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drug Store
  4. 5.1.3 Others
  5. 5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application
  6. 5.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2032)
  8. 5.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2032)
  9. 5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application
  10. 5.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021-2032)
  12. 5.3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2032)
6 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region
  1. 6.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region
  1. 7.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region
  2. 7.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032)
  8. 7.2.2 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032)
  11. 7.3.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Tonghua Dongbao
  2. 8.1.1 Tonghua Dongbao Company Information
  3. 8.1.2 Tonghua Dongbao Business Overview
  4. 8.1.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  6. 8.1.5 Tonghua Dongbao Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Jiangsu Wanbang
  20. 8.4.1 Jiangsu Wanbang Company Information
  21. 8.4.2 Jiangsu Wanbang Business Overview
  22. 8.4.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  24. 8.4.5 Jiangsu Wanbang Recent Developments
  25. 8.5 United Laboratory
  26. 8.5.1 United Laboratory Company Information
  27. 8.5.2 United Laboratory Business Overview
  28. 8.5.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  30. 8.5.5 United Laboratory Recent Developments
  31. 8.6 Sanofi-Aventis
  32. 8.6.1 Sanofi-Aventis Company Information
  33. 8.6.2 Sanofi-Aventis Business Overview
  34. 8.6.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  36. 8.6.5 Sanofi-Aventis Recent Developments
  37. 8.7 Ganlee
  38. 8.7.1 Ganlee Company Information
  39. 8.7.2 Ganlee Business Overview
  40. 8.7.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  42. 8.7.5 Ganlee Recent Developments
  43. 8.8 Biocon
  44. 8.8.1 Biocon Company Information
  45. 8.8.2 Biocon Business Overview
  46. 8.8.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  48. 8.8.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Hypoglycemic Agents and Insulin Analogues Value Chain Analysis
  2. 9.1.1 Oral Hypoglycemic Agents and Insulin Analogues Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Hypoglycemic Agents and Insulin Analogues Production Mode & Process
  6. 9.2 Oral Hypoglycemic Agents and Insulin Analogues Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Hypoglycemic Agents and Insulin Analogues Distributors
  9. 9.2.3 Oral Hypoglycemic Agents and Insulin Analogues Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst